Rate of Pathology Confirmed Adenomyosis in Setting of Endometriosis
Observational
OA: closed
CC0
⚙
AI-generated summary
by qwen3.7-flash, 2026-09-20
ⓘ
This retrospective study found that 55.8% of women with endometriosis undergoing hysterectomy had pathology-confirmed adenomyosis, identifying prior dilation and curettage as a significant risk factor and dyspareunia as protective against the co-occurring condition.
⚙
AI-generated deep summary
by qwen3.7-flash, 2026-09-10
· read from full text
ⓘ
This retrospective cohort study analyzed pathology reports to determine the prevalence of adenomyosis among patients who underwent surgical intervention for endometriosis. The researchers identified a specific subset of individuals with confirmed endometriosis and examined their histological findings to see if adenomyosis was concurrently present in the uterine tissue samples. The analysis revealed that a significant proportion of these patients had pathology-confirmed adenomyosis alongside their endometriosis diagnosis, highlighting the frequent co-occurrence of these two conditions. This paper is centrally about endometriosis and adenomyosis, specifically investigating the rate of adenomyosis detection in patients already diagnosed with endometriosis.
Abstract
INTRODUCTION: In patients with endometriosis presenting with heavy menstrual bleeding or centralized pelvic pain, adenomyosis is frequently suspected. Definitive therapy via hysterectomy may be recommended for treatment and pathologic confirmation. An understanding of the true rate of coincidence of endometriosis and adenomyosis remains unknown. OBJECTIVE: To understand the rates of pathology-confirmed adenomyosis occurring in the setting of endometriosis and identify predictive factors for the diagnosis of adenomyosis. METHODS: Retrospective cross-sectional study of patients undergoing concurrent hysterectomy and excision of endometriosis with pathologic confirmation. Serial pathologic sectioning of the uterus and extensive sampling when no obvious gross lesions identified were performed to evaluate for adenomyosis. P-values less than 5% were considered statistically significant. RESULTS: This study included 95 patients with adenomyosis noted in 53 (55.8%; 95% CI: 45.2%, 66.0%). The average age of participants was 39.7 years (SD=7.3) with an average body mass index of 28.9 kg/m2 (SD=6.5). Most participants were White (82.6%). The primary indications for hysterectomy were pelvic pain (78.9%), menorrhagia (37.9%), and endometriosis (24.2%). There were no statistically significant differences in parity, uterine weight, or endometriosis stage in those with or without adenomyosis. Significant factors included age [adenomyosis: 40.9 years (SD=7.1) vs no adenomyosis: 38.1 years (7.4)] (p=0.026), dyspareunia (52.9% vs 81.0%; p=0.006), and prior dilation and curettage of the uterus (D&C) (24.5% vs 9.5%; p=0.039). There were no statistically significant differences in the history of cesarean section (p=0.493), laparotomy (p=0.165), or laparoscopy (p=0.675) in those with or without adenomyosis. Hormone use at time of surgery and past endometriosis surgery was not predictive of adenomyosis. Forty-seven (53.4%) patients underwent preoperative MRI, 28 (31.8%) ultrasound, and 13 (14.8%) bowel-prepped ultrasound. Adenomyosis confirmatory rates were 40%, 29.4%, and 28.6%, respectively. After adjusting for age, ethnicity, and imaging type, patients with prior D&C were 4.6 times at risk of having adenomyosis (OR: 4.6; 95% CI: 1.19, 23.5). However, patients with dyspareunia were less likely to have adenomyosis (OR: 0.21; 95% CI: 0.06, 0.61). CONCLUSIONS: Among the women with endometriosis, 45.2% did not have coinciding adenomyosis. Future studies should also investigate whether the observed significance between the D&C procedure and pathology-confirmed adenomyosis is due to the procedure itself or the underlying adenomyosis-related symptoms prompting the D&C. This can be executed through retrospective radiologic studies controlled for confounders such as image quality and radiologist variability. Future studies should also continue to identify treatment options that are personalized to the patients’ diagnosis and symptoms. Additionally, there is a need for further investigation into the underlying biological pathways of both endometriosis and adenomyosis.
Full text
562 characters
· extracted from
oa-doi-fallback
· click to expand
SGS Abstracts Supplement: Non-discussed Poster 11Rate of Pathology Confirmed Adenomyosis in Setting of EndometriosisSenthilkumar, S.1; Chen, L.2; Dodoo, C. MS3; Wasson, M. DO4 Author Information 1Mayo Clinic Alix School of Medicine 2Mayo Clinic Arizona Laboratory Medicine and Patholgy 3Mayo Clinic Arizona Statistics 4Mayo Clinic Gynecology Obstetrics & Gynecology 145(5S):p 54S, May 2025. | DOI: 10.1097/AOG.0000000000005851.88 Buy © 2025 by the American College of Obstetricians and Gynecologists. Published by Wolters Kluwer Health, Inc. All rights reserved.
Text is read by the "Ask this paper" AI Q&A widget below.
Extraction quality varies by source — PMC NXML preserves structure
cleanly, OA-HTML may include some navigation residue, and OA-PDF can
have broken hyphenation. The publisher copy
(via DOI)
is the canonical version.
My notes (saved in your browser only)
⚙
Ask this paper
AI returns verbatim quotes from the full text
· source: oa-doi-fallback
ⓘ
Condition tags
endometriosisadenomyosisdyspareunia
Citation neighborhood
(no data yet)
We don't have any in-corpus citations linked to this paper yet.
This is a recent paper (2025) — citers
typically take a year or two to land, and the OpenAlex reference
graph may still be filling in.
Source provenance
- openalex
- last seen: 2026-06-10T17:14:06.276822+00:00
- unpaywall
- last seen: 2026-10-12T06:33:14.382917+00:00
License: CC0
· commercial use OK